Diametric Capital’s Lifecore Biomedical LFCR Stock Holding History

Diametric Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-105,149	Closed	-$391K	–	588
2026 Q1	$391K	Sell	105,149 -12,442	-11%	-$85.9K	0.1%	293
2025 Q4	$962K	Buy	117,591 +91,808	+356%	+$679K	0.26%	96
2025 Q3	$190K	Sell	25,783 -7,689	-23%	-$58.2K	0.07%	338
2025 Q2	$272K	Buy	+33,472	New	+$226K	0.15%	201
2025 Q1	–	Sell	-43,146	Closed	-$321K	–	297
2024 Q4	$321K	Sell	43,146 -32,379	-43%	-$207K	0.22%	142
2024 Q3	$372K	Buy	75,525 +59,403	+368%	+$310K	0.18%	175
2024 Q2	$82.7K	Buy	+16,122	New	+$95.5K	0.04%	316
2024 Q1	–	Sell	-53,702	Closed	-$332K	–	374
2023 Q4	$332K	Buy	+53,702	New	+$373K	0.2%	153
2023 Q2	–	Sell	-64,920	Closed	-$245K	–	414
2023 Q1	$245K	Buy	+64,920	New	+$362K	0.12%	211

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Diametric Capital's LFCR Position: Q2 2026 in Review

Diametric Capital sold out of Lifecore Biomedical (LFCR) in Q2 2026, closing a stake of 105,149 shares — an estimated $391K sold.

Diametric Capital first reported a position in LFCR in Q1 2023 and held it in 9 quarters. The position peaked at $962K in Q4 2025. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

Diametric Capital reported no remaining Lifecore Biomedical position as of Q2 2026 after selling out during the quarter.
Diametric Capital sold 105,149 Lifecore Biomedical shares in Q2 2026, an estimated $391K.
Diametric Capital first reported a position in Lifecore Biomedical in Q1 2023 and held it in 9 quarters.
Diametric Capital's Lifecore Biomedical position peaked at $962K in Q4 2025.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.